The breast cancer expert, in an interview with CancerNetwork®, discussed advances in the field of breast cancer and what we can expect to see in the pipeline moving forward.
The FDA granted a priority review to a new drug application submitted by Seattle Genetics, Inc. for tucatinib to treat patients with HER2-positive breast cancer.
An analysis of the results of the phase III PANTHER trial showed that a combination of tailored dose-dense adjuvant chemotherapy and trastuzumab decreased the relative risk of relapse for patients with HER2-positive breast cancer.
The breast cancer expert spoke about the results presented in the trial, noting the benefit seen with longer follow-up.
The nurse practitioner from UCLA Health spoke about the expanding treatment options in this setting.
The FDA granted accelerated approval to trastuzumab deruxtecan for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer.
The breast cancer expert discussed 2 advances in HER2-positive breast cancer treatment that healthcare providers should look for.
Seattle Genetics announced the development after data was presented at the 2019 San Antonio Breast Cancer Symposium.
Adjuvant therapy with S-1, an oral fluoropyrimidine-based drug, plus endocrine therapy postoperatively significantly increased invasive disease-free survival (IDFS) in patients with HR-positive, HER2-negative breast cancer.
The addition of pertuzumab to the previous standard of trastuzumab plus chemotherapy as an adjuvant therapy for patients with operable HER2-positive early breast cancer continued to reduce the risk for recurrence and death during a 6-year updated analysis.